Evidence map›Paper›PMID 29049083›Full record

ReviewBehavioural pharmacology2017

Ketamine and pharmacological imaging: use of functional magnetic resonance imaging to evaluate mechanisms of action.

Eric A Maltbie, Gopinath S Kaundinya, Leonard L Howell

Open access · greenAbstract readReview
In one paragraph

Review in Behavioural pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Eric A MaltbieaDivision of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center bDepartment of Radiology and Imaging Sciences cDepartment of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia, USA.
Gopinath S Kaundinya
Leonard L Howell
Emory National Primate Research CenterEmory University · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Training In Systems And Integrative Biology NeuroscienceT32NS096050 · NINDS · EMORY UNIVERSITY · PI Yoland Smith · 2016 to 2026
$3.9M
Neuropharmacology of Abused Stimulants in Nonhuman PrimatesK05DA031246 · NIDA · EMORY UNIVERSITY · PI HOWELL, LEONARD L · 2012 to 2016
$619k
NIDA NIH HHS K05 DA031246NIH HHS P51 OD011132NINDS NIH HHS T32 NS096050
6 · The paper itself

Abstract

Ketamine has been used as a pharmacological model for schizophrenia as subanesthetic infusions have been shown to produce temporary schizophrenia-like symptoms in healthy humans. More recently, ketamine has emerged as a potential treatment for multiple psychiatric disorders, including treatment-resistant depression and suicidal ideation. However, the mechanisms underlying both the psychotomimetic and the therapeutic effects of ketamine remain poorly understood. This review provides an overview of what is known of the neural mechanisms underlying the effects of ketamine and details what functional MRI studies have yielded at a systems level focused on brain circuitry. Multiple analytic approaches show that ketamine exerts robust and consistent effects at the whole-brain level. These effects are highly conserved across human and nonhuman primates, validating the use of nonhuman primate models for further investigations with ketamine. Regional analysis of brain functional connectivity suggests that the therapeutic potential of ketamine may be derived from a strengthening of executive control circuitry, making it an intriguing candidate for the treatment of drug abuse. There are still important questions about the mechanism of action and the therapeutic potential of ketamine that can be addressed using appropriate functional neuroimaging techniques.

Indexed as

Magnetic Resonance ImagingAnimalsBrainExcitatory Amino Acid AntagonistsHumansKetamineNeural PathwaysPsychotropic DrugsExcitatory Amino Acid AntagonistsKetaminePsychotropic Drugs

Identifiers

PMID29049083
PMCPMC5687297
OpenAlexW2766190330

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.